Andrew Cakana
Overview
Explore the profile of Andrew Cakana including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
1736
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
De Smedt E, Maes K, Verhulst S, Lui H, Kassambara A, Maes A, et al.
Cancer Res
. 2017 Dec;
78(5):1155-1168.
PMID: 29259009
RAS mutations occur frequently in multiple myeloma (MM), but apart from driving progression, they can also stimulate antitumor effects by activating tumor-suppressive RASSF proteins. Although this family of death effector...
2.
Verhoef G, Robak T, Huang H, Pylypenko H, Siritanaratkul N, Pereira J, et al.
Haematologica
. 2017 Feb;
102(5):895-902.
PMID: 28183846
In the phase 3 LYM-3002 study comparing intravenous VR-CAP with R-CHOP in patients with newly-diagnosed, measurable stage II-IV mantle cell lymphoma, not considered or ineligible for transplant, the median progression-free...
3.
Mateos M, Oriol A, Martinez-Lopez J, Teruel A, Bengoechea E, Palomera L, et al.
Ann Hematol
. 2016 Oct;
95(12):2033-2041.
PMID: 27738789
Trial Registrations: NCT00111319, NCT00443235.
4.
Jokonya L, Musara A, Cakana A, Kalangu K
Surg Neurol Int
. 2016 Jun;
7(Suppl 15):S437-9.
PMID: 27308093
Background: Chronic subdural hematomas (CSDHs) usually occur in elderly patients following minor head trauma. Their occurrence is usually linked to cerebral atrophy secondary to alcohol, old age, or human immunodeficiency...
5.
Orlowski R, Nagler A, Sonneveld P, Blade J, Hajek R, Spencer A, et al.
Cancer
. 2016 May;
122(13):2050-6.
PMID: 27191689
Background: Previous results from an interim analysis of an open-label, randomized, phase 3 study demonstrated that bortezomib combined with pegylated liposomal doxorubicin (PLD) was superior to bortezomib monotherapy in patients...
6.
Reece D, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Blade J, et al.
Blood
. 2014 Sep;
124(16):2498-506.
PMID: 25202139
CAN2007 was a phase 1/2 study of once- and twice-weekly single-agent bortezomib in relapsed primary systemic amyloid light chain amyloidosis (AL) amyloidosis. Seventy patients were treated, including 18 and 34...
7.
Sonneveld P, Goldschmidt H, Rosinol L, Blade J, Lahuerta J, Cavo M, et al.
J Clin Oncol
. 2013 Jul;
31(26):3279-87.
PMID: 23897961
Purpose: To characterize efficacy and safety of bortezomib-based versus nonbortezomib-based induction regimens through an integrated analysis of data from phase III studies in transplantation-eligible patients with previously untreated myeloma. Patients...
8.
Coiffier B, Li W, Henitz E, Karkera J, Favis R, Gaffney D, et al.
Clin Cancer Res
. 2013 Apr;
19(9):2551-61.
PMID: 23549871
Purpose: Identify subgroups of patients with relapsed/refractory follicular lymphoma deriving substantial progression-free survival (PFS) benefit with bortezomib-rituximab versus rituximab in the phase III LYM-3001 study. Experimental Design: A total of...
9.
Garrison Jr L, Wang S, Huang H, Ba-Mancini A, Shi H, Chen K, et al.
Oncologist
. 2013 Jan;
18(1):27-36.
PMID: 23299777
The outlook for transplant-ineligible multiple myeloma patients has improved enormously over recent years with the incorporation of new agents into standard regimens. Novel regimens combine melphalan and prednisone (MP) with...
10.
San Miguel J, Schlag R, Khuageva N, Dimopoulos M, Shpilberg O, Kropff M, et al.
J Clin Oncol
. 2012 Dec;
31(4):448-55.
PMID: 23233713
Purpose: This final analysis of the phase III VISTA trial (Velcade As Initial Standard Therapy in Multiple Myeloma: Assessment With Melphalan and Prednisone) was conducted to determine whether the overall...